Serdar Acar

Dr. Serdar Acar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
BTBilal Turan
Bilal Turan
ASAhmet Necati Sanli
Ahmet Necati Sanli
DSDeniz Esin Tekcan Sanli
Deniz Esin Tekcan Sanli
SASerdar Acar
Serdar Acar
Background Tumor deposits (TD) are well-established prognostic markers in advanced-stage colorectal cancer (CRC), but their independent significance in early-stage disease remains unclear. Current staging systems do not account for TD in node-negative CRC, despite emerging evidence suggesting a potential impact on survival. This study aimed to assess the prognostic impact of TD in early-stage (T1-T3, N0) colon cancer using a large population-based cohort and advanced statistical methods. Methods A retrospective cohort study was conducted using the SEER database (2010–2021), including 111,106 patients with early-stage (T1–T3) colon cancer, of whom 4055 (3.6%) were TD-positive. To minimize baseline imbalances, propensity score matching (1:3 nearest-neighbor; caliper = 0.2) was applied. Overall survival (OS) and disease-specific survival (DSS) were assessed using the Kaplan–Meier analysis and compared with log-rank tests. Multivariate Cox regression was performed to evaluate the independent prognostic impact of TD status in both unmatched and matched cohorts. Results TD-positive patients demonstrated significantly worse overall survival (OS) and disease-specific survival (DSS) compared to TD-negative patients (log-rank p < 0.001). In the unmatched cohort, TD positivity was independently associated with reduced OS (HR: 1.56, 95% CI: 1.48–1.65) and DSS (HR: 2.33, 95% CI: 2.14–2.54; both p < 0.001). These associations remained significant after propensity score matching (OS: HR: 1.44, 95% CI: 1.35–1.54; DSS: HR: 2.17, 95% CI: 1.97–2.40; both p < 0.001). Conclusion TD is an independent prognostic factor in early-stage colon cancer, warranting closer surveillance and reconsideration of treatment strategies. These findings suggest that TD should be integrated into risk stratification models, challenging current staging paradigms.

17 January 2025 in Updates in Surgery
Verified
Journal Article
Open access
PDF file
BTBilal Turan
Bilal Turan
ASAhmet Necati Sanli
Ahmet Necati Sanli
SASerdar Acar
Serdar Acar
This study aimed to compare mucinous carcinoma and adenocarcinoma of the appendix in terms of survival and investigate the risk factors influencing survival. The data for this study were retrieved from the SEER database (SEER Research Plus 17 registries). Patients diagnosed with appendix cancer between 2004 and 2019 were included. Demographic data, such as age, gender, marital status, and year of diagnosis, along with oncological variables like stage, surgery, chemotherapy, radiotherapy, and survival time, were extracted from the SEER database. Pathological subtypes were classified as adenocarcinoma (AC) and mucinous adenocarcinoma (MAC) based on the College of American Pathologists guidelines. Patients with other pathological subtypes or missing data were excluded from the study. This study included 4524 patients, with 2118 (46.8%) classified as AC and 2406 (53.2%) as MAC. There was no significant difference in mean age between AC and MAC groups (63.22 ± 14.30 vs. 59.46 ± 14.07, p = 0.483). AC was more common in males, while MAC was more prevalent in females (46.8% vs. 53.2%; 55.6% vs. 44.4%, p < 0.001, respectively). Married status was high in both groups (p = 0.001). While no difference was found in white race distribution, the black race was more prevalent in the AC group (57.1% vs. 42.9%, p < 0.001). Grade 1 tumors were more frequent in the AC group, whereas Grades 2 and 3 were more common in the MAC group (p < 0.001). Stages 1, 2, and 3 were more prevalent in the AC group, while the majority of MAC cases were at Stage 4. Surgery rates were higher in the AC group (98.6% vs. 96.4%, p < 0.001). Chemotherapy was used more frequently in the MAC group (50.9% vs. 40.6%, p < 0.001), while radiotherapy rates were similar in both groups (p = 0.498). The mean follow-up period was 55.70 ± 47.2 months. Five- and ten-year survival rates for the MAC group were 64.4% and 50.2%, respectively, higher than the AC group’s rates of 54.2% and 39.7% (p < 0.001). The overall risk of mortality was 1.4 times higher in the AC group compared to the MAC group (p < 0.001, HR: 1.377 [CI 95% 1.259–1.507]). While adenocarcinomas and mucinous adenocarcinomas have similar incidences, non-metastatic adenocarcinomas were more frequently observed. In contrast, mucinous adenocarcinomas often exhibited distant metastases. Nevertheless, the survival rate was higher in mucinous adenocarcinomas.

1 June 2025 in Turkish Journal of Trauma and Emergency Surgery
Verified
Journal Article
Open access
SASerdar Acar
Serdar Acar
RCRecep Cetin
Recep Cetin
IZIsmail Zihni
Ismail Zihni
OOOzlem Ozmen
Ozlem Ozmen
MSMehmet Zafer Sabuncuoglu
Mehmet Zafer Sabuncuoglu
CYCeren Yaman
Ceren Yaman
This study investigates the effects of Turkish rose oil (Rosa damascena) on liver damage in rats with experimentally induced obstructive jaundice. A total of 40 Wistar-Albino rats were divided into three groups: Sham (control), Obstructive Jaundice (OJ), and Rose Oil treatment (RO). Obstructive jaundice was induced by bile duct ligation in the OJ and RO groups. The RO group received 100 mg/kg of oral Turkish rose oil daily for seven days. Biochemical analysis showed significantly elevated levels of liver and biliary injury markers, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT), in the OJ group. These markers were significantly reduced in the RO group. Additionally, oxidative stress markers such as malondialdehyde (MDA) and myeloperoxidase (MPO) were lower in the RO group compared to the OJ group. Although levels of antioxidant enzymes, including glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD), were higher in the RO group, the differences were not statistically significant. Interestingly, C-reactive protein (CRP) levels were unexpectedly higher in the RO group than in the OJ group, possibly due to the study duration or dosing protocol. Histopathological examination revealed significant portal inflammation, bile duct proliferation, polymorphonuclear leukocyte (PMNL) infiltration, necrosis, and fibrosis in the OJ group. Conversely, the RO group showed substantial reductions in these pathological features, including milder bile duct proliferation and necrosis (p<0.001). Additionally, connective tissue expansion and collagen deposition were significantly lower in the RO group compared to the OJ group. The anti-inflammatory and hepatoprotective effects of Turkish rose oil, previously reported in the literature, were demonstrated in this study for the first time through oral administration. The findings highlight its potential in mitigating acute liver damage caused by obstructive jaundice. However, some unexpected biochemical results (e.g., elevated CRP and MDA levels) may be attributed to the short study duration, limited sample size, and lack of dose variation. Overall, Turkish rose oil emerges as a promising natural agent with significant hepatoprotective and anti-inflammatory properties. These results suggest that it may serve as a potential therapeutic option for liver damage associated with obstructive jaundice. Further studies are warranted to investigate varying dosages, longer treatment durations, and larger sample sizes to better understand its therapeutic potential.

11 April 2022 in Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Closed access
PDF file
İZİsmail Zihni
İsmail Zihni
MEMümtaz Erakin
Mümtaz Erakin
MBMuhammed Selim Bodur
Muhammed Selim Bodur
IKİsa Karaca
İsa Karaca
SASerdar Acar
Serdar Acar
RÇRecep Çeti̇n
Recep Çeti̇n
Amaç: Meme kanseri dünyada en fazla görülen kadın kanseridir. Kanser büyüyebilir, metastaz yapabilir, ciltte ülser veya nekroza neden olabilir. Kemoterapi ile kontrol edilemeyen meme kanserinde kanama, ülserasyon, enfeksiyon durumlarında palyasyon amaçlı “tuvalet mastektomi veya salvage mastektomi” uygulanmaktadır. Uyguladığımız salvage mastektomi olgularını sunarak literatüre katkı sağlamayı amaçladık.Materyal ve Metot: Kliniğimizde Ocak 2010 - Aralık 2019 tarihleri arasındaki salvage mastektomi vakaları değerlendirildi. Olguların demografik verileri, memedeki tutulum şekli, postoperatif patoloji sonuçları, uzak metastaz ve genel sağ kalım durumu incelendi. Bulgular: Belirtilen tarihler arasında 22 adet tuvalet mastektomi olgusu incelendi. 14 olguda cilde ülsere lezyon, 6 tanesinde ciltte ülser olmadan cilt tutulumu tespit edildi. Hastaların hepsine salvage mastektomi uygulandı. 3 hastaya mastektomi sonrası deri grefti uygulandı. Tüm hastalarda cerrahi sınır negatifti. Hospitalizasyon esnasında hiçbir hastada mortalite görülmemiştir. Genel sağkalım 40 ay (min: 35 ay - max: 60 ay) olarak saptandı.Tartışma - Sonuç: Metastatik meme kanserlerinde salvage mastektomi, konfor ve primer tümörün kontrolünde palyatif olarak uygulanan bir yöntemdir. Çalışmalar göstermiştir ki, primer tümörün temiz cerrahi sınırla çıkarılması metastatik meme kanserinde sağkalım avantajı ve artmış hayat kalitesi sağlar. Bu hastalar multidisipliner onkolojik yaklaşımla değerlendirilmeli, cerrahiye uygun hastaların seçimi ve takibi bu ekiple yapılmalıdır.

24 May 2021 in Turkish Journal of Colorectal Disease
Verified
Journal Article
Closed access
MSMehmet Zafer Sabuncuoğlu
Mehmet Zafer Sabuncuoğlu
İZİsmail Zihni
İsmail Zihni
ISİsa Sözen
İsa Sözen
GÇGirayhan Çelik
Girayhan Çelik
BTBilal Turan
Bilal Turan
SASerdar Acar
Serdar Acar

15 June 2023
Verified
Book
Open access
PDF file
AAAdem Aslan
Adem Aslan
TMTuba Mert
Tuba Mert
BUBurak Uçaner
Burak Uçaner
OHOguz Hancerliogullari
Oguz Hancerliogullari
ÇKÇağdaş Karaman
Çağdaş Karaman
BMBerke Manoğlu
Berke Manoğlu
Cerrahi’nin Tarihçesi Adem ASLAN Cerrahi Hastalarda Sıvı ve Elektrolit Yönetimi Tuba MERT Şok Burak UÇANER Cerrahi Enfeksiyon Oğuz HANÇERLİOĞULLARI Travma Cerrahisi Çağdaş KARAMAN Cerrahi Yara İyileşmesi Mehmet Sabri ÇİFTÇİ Cerrahi Kanama ve Transfüzyon Serdar ACAR Baş Boyun Cerrahisinde Yenilikler Seda SEZEN GÖKTAŞ Tiroid Hastalıklarına Yaklaşım Zeynep ANADOLULU Paratiroid Hastalıklarına Yaklaşım Murat ÖZKARA Benign Meme Hastalıklarına Yaklaşım Nimet SÜSLÜ Malign Meme Hastalıkları Cerrahisi Murat KARTAL Meme Kanserinde Sentinel Lenf Nodu Biyopsisi Furkan SAVAŞ Onkoplastik Meme Cerrahisi Hasan Turgut AYDIN Diyafragma Cerrahisi İsa KARACA Özofagus Kanseri Cerrahisi Mevlüt YORDANAGİL Akalazya: Tanı ve Tedavi Sacit Altuğ KESİKLİ Güncel Mide Cerrahisi Ali DURAN Midenin Selim Hastalıklarına Yaklaşım Mehmet ARSLAN Güncel Bariatrik Cerrahi Yunus YAPALAK Obezitenin Cerrahi Dışı Tedavi Yöntemleri Elnur HÜSEYNOV Safra Kesesi Cerrahisi Özkan SUBAŞI Safra Yolları Girişimleri Mirkhalig JAVADOV Emrah KARATAY Pankreas Hastalıkları ve Tedavisi Gökhan GARİP Açık ve Laparoskopik Splenektomi Erhan ERÖZ Sürrenal Hastalıkları ve Cerrahisi Baran MOLLAVELİOĞLU Güncel Apandisit Cerrahisi Sibel ÖZKARA Kasık Fıtığının Açık ve Laparoskopik Cerrahisi Murat DEMİR Ventral Herni Cerrahisi Abdullah AS Malign ve Benign Hastalıklarda Karaciğer Cerrahisi Seda BAŞTÜRK Karaciğer Kistlerinin Tedavisi Mevlüt Harun AĞCA Karaciğer Kistlerinde PAIR Uygulaması Mehmet Emin UNUTMAZ Endoskopik Retrograd Kolanjiyopankreatografi ERCP Mikail UYAN HIPEC, Sıcak Kemoterapi Gözde ERTUNÇ AÇIKGÖZ Transanal Endoskopik Mikrocerrahi (TEM) Serdar ACAR İnce Bağırsak Cerrahisi Serkan YILMAZ Gastrointestinal Sistem Kanamaları Mesud FAKİRULLAHOĞLU Hasar Kontrol Cerrahisi Sümeyra GÜLER Laparoskopik Diagnostik Girişimler Bilal TURAN Endsokopik Submukozal Diseksiyon Mehmet BİÇER Laparoskopik İnce Barsak Cerrahisi Mesut YUR Güncel Kolorektal Cerrahi Barış CANDAN Benign Kolorektal Hastalıklara Yaklaşım Osman AKDOĞAN Mehmet KARAHAN Rektal Prolapsus Cerrahisi Yasin Orhan ERKUŞ Karın Duvarı Tümörlerine Yaklaşım Göktürk GÜRSOY Proktolojide Güncel Tedavi Yöntemleri Muhammet Fikri KÜNDEŞ Transplantasyon Emil HÜSEYİNOĞLU Bahtiyar MUHAMMEDOĞLU Genel Cerrahide Lazer Teknolojisinin Kullanımı Şükran ÇAVDAR Murat Bulut ÖZKAN Cerrahi Komplikasyon Yönetimi Gizem FIRTINA Perkütan Abdominal Apse, Sıvı Drenajı Tuğberk BAŞTÜRK Cerrahide Stapler Teknolojisi ve Enerji Aletleri Oğuzhan ÇÖĞÜRLÜ Jinekolojide Minimal İnvaziv Cerrahi Burcu AYDIN BOYAMA İleri Endoskopik Girişimler Girayhan ÇELİK Anormal Uterin Kanama ve Cerrahisi Cansu ÖNAL KANBAŞ Endoscopik Ultrasonografi Mahmut Baran YERLİKAYA Batın Kapama Yöntemlerinde Yenilikler İbrahim KILINÇ Pelvik Taban Kusurlarında Cerrahi Uygulamalar Tamer TOPALOĞLU Omurga Cerrahisi Furkan SOY Halil GÖK Pediatrik Yaş Grubunda Pilonidal Sinüs Tedavisine Güncel Yaklaşımlar Gonca GERÇEL Ali İhsan ANADOLULU Pediatrik Minimal İnvaziv Uygulamalar Ali İhsan ANADOLULU Gonca GERÇEL Jinekolojik Onkolojik Aciller Nur Cansu YILMAZ BALDAN Cerrahide Anestezi Yönetimi Fatma OKUCU Robotik Cerrahi Teknolojisinin Gelişimi Berke MANOĞLU